H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Lyell Immunopharma to $11 from $12 and keeps a Buy rating on the shares post the Q3 results.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LYEL:
- Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors
- Lyell Immunopharma initiated with a Buy at H.C. Wainwright
- Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors
- Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
- Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer